Articles

Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies

Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK
Institute for Experimental Cancer Research in Pediatrics, Goethe-University, Frankfurt, Germany
Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK
Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK
Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK
Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK
Ernest and Helen Scott Haematological Research Institute, Leicester Cancer Research Centre, University of Leicester, Leicester Royal Infirmary, UK
Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK;Department of Molecular and Clinical Cancer Pharmacology, Institute of Translational Medicine, University of Liverpool, UK
Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, UK;Department of Molecular and Clinical Cancer Pharmacology, Institute of Translational Medicine, University of Liverpool, UK
Vol. 104 No. 5 (2019): May, 2019 https://doi.org/10.3324/haematol.2018.204701